Pricing Log in Create free account
Friday 6 November 2026 Export SRRK’s income statement to Excel — free account

Scholar Rock Holding Corporation

SRRK Healthcare Biotechnology

Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.

EPS
+14.3%
Free cash flow
+8.88%
Total debt
+294.3%

Quarter to June 2026, against a year earlier

46.94 1.44 +3.16%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
−7.3×
Dividend yield
—
F-score
3/9
Altman Z
1.14
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Scholar Rock Holding Corporation (SRRK) P/E ratio

Alert me on P/E ratio

Scholar Rock Holding Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Mar 2022 0.0× —
Dec 2021 0.0× —
Sep 2021 0.0× —
Jun 2021 0.0× —
9 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
BLTE Belite Bio, Inc. Sponsored ADR compare n/m
ERAS Erasca, Inc. compare n/m
CGON CG Oncology, Inc. compare n/m
SRRK Scholar Rock Holding Corporation n/m
MANE Veradermics Incorporated compare n/m
IMVT Immunovant, Inc. compare n/m
PTCT PTC Therapeutics, Inc. compare n/m
KOD Kodiak Sciences Inc. compare n/m
COGT Cogent Biosciences, Inc. compare n/m
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on SRRK